The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Despite Keytruda being set to continue its rapid expansion, plus growth from other new brands, Merck forecasts growth in 2018 to be even more limited like 2017. It expects to achieve less than 1% ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Jimmy Investor. In this article, we will summarize ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...